| 04/05 | ANAPTYSBIO, INC Management's Discussion and Analysis of Financial Condition and Result.. |  |
| 04/05 | AnaptysBio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022 | |
| 04/05 | AnaptysBio Announces First Quarter 2022 Financial Results and Provides Pipeline Update | |
| 04/05 | AnaptysBio Announces First Quarter 2022 Financial Results and Provides Pipeline Update | |
| 29/04 | ANAPTYSBIO, INC : Change in Directors or Principal Officers, Financial Statements and Exhi.. | |
| 28/04 | Anaptysbio announces positive anb032 (anti-btla agonist) top-line phase 1 data and prov.. | |
| 28/04 | ANAPTYSBIO : Announces Positive ANB032 (anti-BTLA agonist) Top-Line Phase 1 Data and Provi.. | |
| 27/04 | ANAPTYSBIO, INC : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K) | |
| 27/04 | AnaptysBio Announces Positive ANB032 (anti-BTLA agonist) Top-Line Phase 1 Data and Prov.. | |
| 27/04 | Anaptysbio, Inc. Announces Positive Anb032 (Anti-Btla Agonist) Top-Line Phase 1 Data an.. | |
| 22/03 | Anaptysbio appoints daniel faga as interim chief executive officer | |
| 21/03 | ANAPTYSBIO, INC : Change in Directors or Principal Officers (form 8-K) | |
| 21/03 | AnaptysBio Taps Former Mirati Therapeutics' COO as Interim CEO | |
| 21/03 | AnaptysBio Appoints Daniel Faga As Interim Chief Executive Officer | |
| 21/03 | AnaptysBio, Inc. Announces Management Changes | |
| 21/03 | AnaptysBio, Inc. Announces Executive Changes | |
| 15/03 | AFTER HOURS WATCH LIST SCORECARD : Gtlb, anab, coup | |
| 15/03 | AnaptysBio to Halt Imsidolimab Development for Acne After Trial; Shares Sink in Pre-Mar.. | |
| 14/03 | MT NEWSWIRES AFTER HOURS WATCH LIST : Gtlb, anab, coup | |
| 14/03 | AnaptysBio to Halt Imsidolimab Development for Acne After Trial; Shares Plunge 13% Afte.. | |
| 14/03 | ANAPTYSBIO : Reports Imsidolimab ACORN Phase 2 Clinical Trial Data in Moderate-to-Severe A.. | |
| 14/03 | ANAPTYSBIO, INC : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K) | |
| 14/03 | AnaptysBio Reports Imsidolimab ACORN Phase 2 Clinical Trial Data in Moderate-to-Severe .. | |
| 14/03 | AnaptysBio, Inc Reports Imsidolimab Acorn Phase 2 Clinical Trial Data in Moderate-To-Se.. | |
| 08/03 | Anaptysbio announces fourth quarter and full year 2021 financial results and provides p.. | |
| 07/03 | AnaptysBio Swings to Loss in Q4, Revenue Plunges; Shares Drop Pre-Bell | |
| 07/03 | ANAPTYSBIO : Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Pi.. | |
| 07/03 | ANAPTYSBIO, INC Management's Discussion and Analysis of Financial Condition and Result.. | |
| 07/03 | AnaptysBio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021 | |
| 07/03 | AnaptysBio, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 202.. | |
| 07/03 | AnaptysBio Announces Fourth Quarter and Full Year 2021 Financial Results and Provides P.. | |
| 07/03 | AnaptysBio Announces Fourth Quarter and Full Year 2021 Financial Results and Provides P.. | |
| 02/02 | Tres ETFs en la nube |  |
| 13/01 | TRANSCRIPT : AnaptysBio, Inc. Presents at JPMorgan 40th Annual Healthcare Conference, Jan-.. | |
| 05/01 | AnaptysBio To Present at the 40th Annual J.P. Morgan Healthcare Conference | |
| 2021 | AnaptysBio Files $300 Million Mixed Shelf | |
| 2021 | INSIDER SELL : Anaptysbio | |
| 2021 | Hexima Names New Chief Development Officer | |
| 2021 | ANAPTYSBIO, INC : Completion of Acquisition or Disposition of Assets (form 8-K) | |
| 2021 | Anaptysbio announces appointment of daniel faga to board of directors | |
| 2021 | ANAPTYSBIO, INC : Change in Directors or Principal Officers (form 8-K) | |
| 2021 | AnaptysBio Announces Appointment of Daniel Faga to Board of Directors | |
| 2021 | AnaptysBio, Inc. Announces Appointment of Daniel Faga to Board of Directors | |
| 2021 | AnaptysBio To Present at the 2021 Jefferies London Healthcare Conference | |
| 2021 | AnaptysBio To Present at the 2021 Jefferies London Healthcare Conference | |
| 2021 | ANAPTYSBIO : Announces Positive Rosnilimab Healthy Volunteer Phase 1 Top-Line Data - Form .. | |
| 2021 | ANAPTYSBIO, INC : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K) | |
| 2021 | AnaptysBio Announces Positive Rosnilimab Healthy Volunteer Phase 1 Top-Line Data | |
| 2021 | AnaptysBio, Inc. Announces Positive Rosnilimab Healthy Volunteer Phase 1 Top-Line Data | |
| 2021 | AnaptysBio Announces Third Quarter 2021 Financial Results and Provides Pipeline Updates.. | |
| 2021 | ANAPTYSBIO, INC Management's Discussion and Analysis of Financial Condition and Result.. | |
| 2021 | AnaptysBio, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended S.. | |
| 2021 | AnaptysBio Announces Third Quarter 2021 Financial Results and Provides Pipeline Updates | |
| 2021 | INSIDER SELL : Anaptysbio | |
| 2021 | ANAPTYSBIO : Agrees With Sagard Healthcare to Monetize Portion of Jemperli Royalties | |
| 2021 | ANAPTYSBIO, INC : Entry into a Material Definitive Agreement (form 8-K) | |
| 2021 | ANAPTYSBIO : Announces Agreement to Monetize Portion of JEMPERLI Royalties for $250 Millio.. | |
| 2021 | AnaptysBio Announces Agreement with Sagard Healthcare Royalty Partners | |
| 2021 | ANAPTYSBIO : Presents Updated Data From Imsidolimab Phase 2 GALLOP Trial in Generalized Pu.. | |
| 2021 | ANAPTYSBIO, INC : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K) | |
| 2021 | ANAPTYSBIO : Presents updated data from imsidolimab phase 2 gallop trial in generalized pu.. | |
| 2021 | ANAPTYSBIO : Mid-Stage Trial Shows Imsidolimab Drug Candidate May Have Potential Against P.. | |
| 2021 | ANAPTYSBIO : Presents Updated Data From Imsidolimab Phase 2 GALLOP Trial in Generalized Pu.. | |
| 2021 | AnaptysBio Presents Updated Data From Imsidolimab Phase 2 GALLOP Trial in Generalized P.. | |
| 2021 | ANAPTYSBIO : Corporate Presentation September 2021 | |
| 2021 | ANAPTYSBIO : to Participate in the H.C. Wainwright 23rd Annual Global Investment Conferenc.. | |
| 2021 | SECTOR UPDATE : Health Care Stocks Discounted Wednesday | |
| 2021 | SECTOR UPDATE : Health Care Stocks Underperforming Market Wednesday | |
| 2021 | ANAPTYSBIO : Fda grants accelerated approval of jemperli (dostarlimab-gxly) for dmmr recur.. | |
| 2021 | SECTOR UPDATE : Health Care Stocks Flat To Lower Premarket Wednesday | |
| 2021 | NORTH AMERICAN MORNING BRIEFING : Stock Futures Slip as Fed Minutes Eyed | |
| 2021 | UPDATE : AnaptysBio Gets FDA's Accelerated Approval for Second Indication of GlaxoSmithKli.. | |
| 2021 | ANAPTYSBIO : Receives FDA's Accelerated Approval for Second Indication of GlaxoSmithKline'.. | |
| 2021 | AnaptysBio Up 10% on GSK Drug Indication Approval | |
| 2021 | FDA Grants Accelerated Approval of JEMPERLI (dostarlimab-gxly) for dMMR Recurrent or Ad.. | |
English (USA)
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Italiano
Nederlands (Nederland)
Nederlands (België)
bourse
Rapport
